Abstract
The influence of lipid-lowering therapy employing a historic cohort study design was assessed following heart transplantation. Lipid-lowering therapy appears to confer a survival benefit in cardiac transplant recipients who survive beyond the first year.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Adult
-
Cholesterol / blood
-
Cohort Studies
-
Female
-
Gemfibrozil / therapeutic use*
-
Heart Transplantation / mortality*
-
Humans
-
Hyperlipidemias / drug therapy*
-
Hypolipidemic Agents / therapeutic use*
-
Male
-
Middle Aged
-
Survival Analysis
-
Triglycerides / blood
Substances
-
Hypolipidemic Agents
-
Triglycerides
-
Cholesterol
-
Gemfibrozil